CA Patent

CA2971868A1 — Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same

Assigned to Chiesi Farmaceutici SpA · Expires 2016-07-21 · 10y expired

What this patent protects

The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet…

USPTO Abstract

The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.

Drugs covered by this patent

Patent Metadata

Patent number
CA2971868A1
Jurisdiction
CA
Classification
—
Expires
2016-07-21
Drug substance claim
No
Drug product claim
No
Assignee
Chiesi Farmaceutici SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.